Drugs / KYN-5356
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06225115 | Dec 2023 → Oct 2024 | schizophrenia | Kynexis B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07191483 | Aug 2025 → Oct 2026 expected | schizophrenia | Kynexis B.V. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KYN-5356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06225115 ↗ |
| Route | Oral | “KYN-5356, oral tablet” NCT06225115 ↗ |